title: Incidence of symptomatic urinary tract infections in HIV seropositive patients and the use of cotrimoxazole as prophylaxis against Pneumocystis carinii pneumonia.
abstract: OBJECTIVE
  To determine the incidence of symptomatic urinary tract infections in HIV seropositive patients and to assess whether this varies with stage of disease, risk group or the use of co-trimoxazole as prophylaxis against Pneumocystis carinii pneumonia.
  
  
  METHODS
  A retrospective case note review of 175 HIV-infected patients attending The Royal London Hospital between July 1988 and December 1992 was performed. A urinary tract infection was defined as a pure culture of > or = 10(5) colony forming units in a mid-stream specimen of urine from a patient with symptoms consistent with a urinary tract infection.
  
  
  RESULTS
  Urinary tract infections occurred in 10 (5.7%) of 175 patients, with an incidence of 1.49 per hundred patient years. Urinary tract infections were significantly more common in patients with AIDS or a CD4 lymphocyte count below 0.2 x 10(9)/l (or both) when compared to those without AIDS and a CD4 lymphocyte count above 0.2 x 10(9)/l (5.4 vs. 0.5 urinary tract infections per hundred patient years, p = 0.00005). Women with AIDS or a CD4 count below 0.2 x 10(9)/l (or both) had an incidence of urinary tract infection of 18.5 per hundred patient years. No significant difference was found between the incidence of urinary tract infections in those taking co-trimoxazole as Pneumocystis carinii pneumonia prophylaxis and those taking alternative or no prophylaxis (2.6 vs 6.4 per hundred patient years, p = 0.39).
  
  
  CONCLUSIONS
  Urinary tract infection represents a considerable health problem amongst HIV infected patients. Our data show that urinary tract infections are more common in patients with advanced compared with early HIV infection. Cotrimoxazole, when taken by patients as prophylaxis against Pneumocystis carinii pneumonia did not appear to reduce the incidence of urinary tract infection.
authors.affiliation: Ambrose King Centre, Royal London Hospital, UK.
authors.forename: J K
authors.initials: JK
authors.lastname: Evans
authors.forename: A
authors.initials: A
authors.lastname: McOwan
authors.forename: R J
authors.initials: RJ
authors.lastname: Hillman
authors.forename: G E
authors.initials: GE
authors.lastname: Forster
mesh_terms: D018791:CD4 Lymphocyte Count; D005260:Female; D006679:HIV Seropositivity / Q000150:complications*; D006716:Homosexuality; D006801:Humans; D015994:Incidence; D008297:Male; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D019966:Substance-Related Disorders; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000150:complications / Q000453:epidemiology*
chemical_list: D015662:Trimethoprim, Sulfamethoxazole Drug Combination